Program, Ides of March 2012

First Page		Document Content
Hepatitis Autoimmune hepatitis Elevated transaminases Liver disease Alanine transaminase Liver Cholestasis Biomarker Bilirubin Medicine Hepatology Hepatotoxicity		Program, Ides of March 2012 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 34,15 KB Share Document on Facebook

	Hepatol Int:453–471 DOIs12072GUIDELINES Acute-on-chronic liver failure: consensus recommendations DocID: 1vpdu - View Document
	A Rational Evidence-based Approach to Abnormal Liver Tests Jane D. Ricaforte-Campos, MD FPCP, FPSG, FPSDE 2013 HSP Post-graduate Course DocID: 1vnki - View Document
	Assessment RunCarcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3. Colon adenocarcinoma, 4-5. Urothelial carcinoma DocID: 1vhkc - View Document
	Liver cancer patient-derived xenografts to improve disease management in childhood and adolescence: perspectives and challenges of personalized medicine. Stefano Cairo1, Aurore Gorse1, Delphine Nicolle1, Erwan Selingue1, DocID: 1vh8d - View Document
	en13 Leon Bobrowski et al.: Ranked Modeling of Liver Diseases Sequence, enRanked Modeling of Liver Diseases Sequence Leon Bobrowski1,2, Tomasz Łukaszuk1, Hanna Wasyluk3 DocID: 1vebG - View Document